ArticleFrontiers in cardiovascular medicine2026
Patterns and risk factors of hyperkalemia recurrence among heart failure patients.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hyperkalemia, a life-threatening electrolyte condition, is linked to arrhythmias and sudden death, but evidence on its recurrence in heart failure (HF) patients is limited. Methods: We conducted a cohort study using de-identified EHR data from TriNetX Dataworks USA (study period: January 1, 2019, to June 30, 2023). HF patients who experienced hyperkalemia were included. Study outcomes included the percentage experiencing recurrent hyperkalemia (K+ >5.0 mmol/L), number and timing of recurrences, and K+ at each recurrence. Risk factors for hyperkalemia recurrence were identified using multivariable logistic regression and validated with Monte Carlo simulation. Subgroup analyses were performed for patients without baseline CKD (i.e., eGFR >60 mL/min/1.73 m² and no CKD/ESRD diagnosis). Results: The study cohort comprised 15,512 patients (median age 68 years, 42.3% female, 60.5% White, 21.4% Black). Within 12 months, recurrent hyperkalemia was commonly observed in the full cohort (49.5%) and No-CKD subgroup (37.3%). Mean number of recurrences was 2.5 and 2.0, respectively; mean K+ at each recurrence was ∼5.5 mmol/L; and time to recurrence decreased with each successive event. Significant risk factors for recurrence included history of hyperkalemia (OR 2.3, 95% CI: 2.1-2.5), hypertension, advanced CKD, immunosuppressant therapy, and malignancy. Conclusions: In this real-world cohort of HF patients, hyperkalemia recurrence was common regardless of renal function status, with increasing frequency and decreasing time intervals between subsequent recurrences. History of hyperkalemia was the strongest risk factor for recurrent hyperkalemia. Further research focused on hyperkalemia management in HF patients is warranted to prevent future recurrences and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.